Clinical study of total glucosides of paeony for the treatment of diabetic kidney disease in patients with diabetes mellitus
- 335 Downloads
Background and aim
Total glucosides of paeony (TGP), an active compound extracted from dried roots of Paeonia lactiflora Pall, have anti-inflammatory effects. This study investigated the efficacy and safety of TGP for treating diabetic kidney disease (DKD) in type 2 diabetes mellitus patients.
An open-label, prospective, randomized, parallel-group, single-site study involving 76 patients with DKD. Patients were randomized into two groups: losartan group (n = 38), treated with losartan 100 mg/day for 6 months and TGP group (n = 38), treated with TGP 1800 mg/day and losartan 100 mg/day for 6 months. Serum hs-CRP, MCP-1, and TNF-α were determined before and after treatment. Urinary albumin excretion rate (UAER), fasting blood glucose, serum creatinine, and lipid profiles were examined.
At the end-point, UAER decreased in the TGP group compared with baseline. UAER in the losartan group decreased to a level lower than before treatment. The rate of decline in the losartan group was significantly lower than the TGP group. There were no significant differences in serum creatinine and albumin levels between TGP and losartan groups at the end-point. Serum hs-CRP, MCP-1, and TNF-α levels were significantly lower in both groups after treatment. After treatment, serum hs-CRP, MCP-1, and TNF-α in the TGP group decreased more than the losartan group. Positive correlations were observed between UAER and hs-CRP, MCP-1, and TNF-α. No statistically significant difference in side effects was observed between groups.
Our study showed that TGP treatment could reduce the albuminuria and inflammatory markers in type 2 diabetes mellitus patients with DKD.
KeywordsDiabetic kidney disease Total glucosides of paeony Albumin excretion rate Inflammation
This study was funded by grants from the National Natural Science Foundation of China (No. 80270813).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Clinical Research Committee of the First Affiliated Hospital of Anhui Medical University and with the 1964 Helsinki Declaration and its later amendments.
Informed consent was obtained from all individual participants included in the study.
- 1.(2003) USRDS: the United States Renal Data System. Am J Kidney Dis 42:1–230Google Scholar
- 9.Zhou Q, Li ZG (2013) Pharmaceutical effects of total glucosides of peony and its application in autoimmune disease. Chin J New Drugs Clin Rem 22:687–691Google Scholar
- 10.Zhang MO, Wang YJ, Chen HY et al (2014) Efficacy and safety of Pafulin in treatment of mesangial proliferative nephritis. Zhejiang Clin Med J 36:924–927Google Scholar
- 11.Mo H, Chen YD (2014) A clinical study of total glucosides of paeony for treatment of patients with systemic lupus erythematosus accompanied by leucopenia. Chin J TCM WM Crit Care 21:104–107Google Scholar
- 19.Zhang CQ, Wu XX, Wu YG et al (2014) Effect of total glucosides of paeony on TRL signal pathway in the kidney from diabetic rats. Chin Pharmacol Bull 30:354–359Google Scholar